TRAF3 (TNF receptor-associated factor 3) variants and mutations
TRAF3 (also known as TNF receptor-associated factor 3) is a human protein-coding gene encoding a TNF receptor-associated factor 3 protein. It coordinates signaling downstream of TNF-receptor-family and innate immune receptors, restraining some NF-kappaB pathways while promoting antiviral interferon responses. Biallelic or dominant pathogenic variants can cause immunodeficiency, and somatic loss contributes to B-cell malignancies. This analysis covers 841 TRAF3 variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes Herpetic encephalitis, Eczematoid dermatitis, and asthma. Example TRAF3 variants include E2D, E2Q, and E2E.
Variant analysis overview
- Gene: TRAF3
- Protein: TNF receptor-associated factor 3
- UniProt accession: Q13114
- Organism: Homo sapiens
- Variants analyzed: 841
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 661 unspecified-consequence records; 102 synonymous variants; 68 missense variants; 2 in-frame deletions; 3 splice-region variants; 2 stop-gained variants; 2 frameshift variants; 1 substitution
- Prediction scores: 697 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Herpetic encephalitis, Eczematoid dermatitis, asthma, allergic rhinitis, immunodeficiency 132b, atopic eczema, type 2 diabetes mellitus, Abnormality of the skeletal system, multiple sclerosis, TRAF3 haploinsufficiency, plasma cell myeloma, inborn error of immunity.
Protein structure and variant hotspots
- Protein features: 1 domains; 1 post-translational modification sites.
- Structural context: 161 variants have structural context.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TRAF3 variants
Examples include E2D, E2Q, E2E, S3L, S3P, S3S, S4G, S4I. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- E2D (p.Glu2Asp), gnomAD rs1435980220, REVEL 0.06, MetaLR 0.04
- E2Q (p.Glu2Gln), ExAC rs760828108, gnomAD rs760828108
- E2E (p.Glu2Glu), gnomAD 14-102870207-G-A, CADD 8.45
- S3L (p.Ser3Leu), rs1052600602, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61027, TOPMed rs1052600602, REVEL 0.14, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- S3P (p.Ser3Pro), rs2542429932, ClinGen CA391069503, ClinVar RCV003876796, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- S3S (p.Ser3Ser), gnomAD 14-102870210-G-T, CADD 0.26
- S4G (p.Ser4Gly), TOPMed rs1292487225
- S4I (p.Ser4Ile), gnomAD rs1369830104, REVEL 0.18, MetaLR 0.12
- S4R (p.Ser4Arg), TOPMed rs1292487225, REVEL 0.21, MetaLR 0.07
- K5E (p.Lys5Glu), TOPMed rs1335113299, gnomAD rs1335113299, REVEL 0.17, MetaLR 0.11
- K5R (p.Lys5Arg), ExAC rs755457663, gnomAD rs755457663, REVEL 0.19, MetaLR 0.06
- K6E (p.Lys6Glu), rs1292084798, ClinGen CA391069523, ClinVar RCV001363835, TOPMed rs1292084798, REVEL 0.24, MetaLR 0.11, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- K6N (p.Lys6Asn), TOPMed rs1281040764, gnomAD rs1281040764, REVEL 0.03, MetaLR 0.05
- K6R (p.Lys6Arg), TOPMed rs937992126, gnomAD rs937992126, REVEL 0.12, MetaLR 0.11
- D8A (p.Asp8Ala), ExAC rs779404357, gnomAD rs779404357, REVEL 0.18, MetaLR 0.08
- D8E (p.Asp8Glu), TOPMed rs1218851959, gnomAD rs1218851959, REVEL 0.08, MetaLR 0.06
- D8G (p.Asp8Gly), ExAC rs779404357, gnomAD rs779404357, REVEL 0.12, MetaLR 0.08
- D8V (p.Asp8Val), ExAC rs779404357, gnomAD rs779404357, REVEL 0.27, MetaLR 0.11
- D8N (p.Asp8Asn), gnomAD 14-102870223-G-A, REVEL 0.19, CADD 22.10
- S9F (p.Ser9Phe), rs1280119958, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61024, TOPMed rs1280119958, AlphaMissense 0.08, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- S9T (p.Ser9Thr), rs2542430125, ClinGen CA391069546, ClinVar RCV003648118, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- S9P (p.Ser9Pro), gnomAD 14-102870226-T-C, REVEL 0.02, CADD 0.43
- S9S (p.Ser9Ser), rs1011145131, gnomAD 14-102870228-T-C, CADD 0.52
- P10L (p.Pro10Leu), rs542494294, ClinGen CA7359138, ClinVar RCV003033507, ClinVar RCV004681601, REVEL 0.07, MetaLR 0.07, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- P10S (p.Pro10Ser), rs1302170239, ClinGen CA391069553, ClinVar RCV003830149, TOPMed rs1302170239, REVEL 0.01, MetaLR 0.04, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- P10T (p.Pro10Thr), rs1302170239, ClinGen CA391069551, ClinVar RCV001972076, TOPMed rs1302170239, REVEL 0.01, MetaLR 0.05, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- G11D (p.Gly11Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G11S (p.Gly11Ser), gnomAD rs1203054993, REVEL 0.07, MetaLR 0.05
- p.Gly11 Pro17del, rs1888255964, gnomAD 14-102870228-TCCT, CADD 14.60
- G11G (p.Gly11Gly), rs758876295, gnomAD 14-102870234-C-T, CADD 0.94
- A12T (p.Ala12Thr), rs139127242, ClinGen CA7359140, cosmic curated COSV61026, ClinVar RCV001057503, REVEL 0.03, MetaLR 0.04, Conflicting interpretations, Herpes simplex encephalitis, susceptibility to, 3; not specified
- A12V (p.Ala12Val), rs746483559, ClinGen CA7359141, ClinVar RCV001305059, ExAC rs746483559, REVEL 0.22, MetaLR 0.08, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- A12A (p.Ala12Ala), rs199639339, gnomAD 14-102870237-G-A, CADD 0.07
- L13A (p.Leu13Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L13V (p.Leu13Val), gnomAD 14-102870238-C-G, REVEL 0.03, CADD 0.28
- L13Q (p.Leu13Gln), gnomAD 14-102870239-T-A, REVEL 0.03, CADD 20.70
- Q14* (p.Gln14Ter), NCI-TCGA TCGA novel, 1000Genomes rs2139827117, CADD 35.00, Variant assessed as somatic; high impact.
- Q14H (p.Gln14His), rs1013802030, ClinGen CA267124521, ClinVar RCV001038981, ClinVar RCV005762150, REVEL 0.06, MetaLR 0.06, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- Q14P (p.Gln14Pro), cosmic curated COSV61025, TOPMed rs896716603, gnomAD rs896716603, REVEL 0.06, MetaLR 0.09
- N16T (p.Asn16Thr), cosmic curated COSV61023, ExAC rs780863420, gnomAD rs780863420, REVEL 0.08, MetaLR 0.05
- P17L (p.Pro17Leu), rs745517643, ClinGen CA7359144, ClinVar RCV003870218, ExAC rs745517643, REVEL 0.18, MetaLR 0.06, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- P17R (p.Pro17Arg), ExAC rs745517643, TOPMed rs745517643, gnomAD rs745517643, REVEL 0.16, MetaLR 0.11, Uncertain significance
- P17Q (p.Pro17Gln), gnomAD 14-102870251-C-A, REVEL 0.17, CADD 19.80
- P17P (p.Pro17Pro), rs1166121049, gnomAD 14-102870252-G-A, CADD 0.09
- P18L (p.Pro18Leu), rs145456077, cosmic curated COSV10069, ESP rs145456077, ExAC rs145456077, REVEL 0.03, MetaLR 0.04, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- P18R (p.Pro18Arg), rs145456077, ClinGen CA391069600, ClinVar RCV000577847, ESP rs145456077, REVEL 0.02, MetaLR 0.05, Uncertain significance, Ependymoma
- P18P (p.Pro18Pro), rs775197332, gnomAD 14-102870255-G-A, CADD 0.28
- L19L (p.Leu19Leu), rs762827715, gnomAD 14-102870258-A-G, CADD 0.33
- K20N (p.Lys20Asn), Ensembl rs1888259233, REVEL 0.06, MetaLR 0.08
- K20R (p.Lys20Arg), Ensembl rs2139827283
- L21Q (p.Leu21Gln), gnomAD 14-102870263-T-A, REVEL 0.08, CADD 16.50
- H22Y (p.His22Tyr), gnomAD 14-102870265-C-T, REVEL 0.05, CADD 13.40
- H22H (p.His22His), rs768589372, gnomAD 14-102870267-C-T, CADD 1.57
- T23A (p.Thr23Ala), rs1019409633, ClinGen CA267124556, ClinVar RCV003648697, Ensembl rs1019409633, REVEL 0.01, MetaLR 0.03, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- T23I (p.Thr23Ile), ExAC rs774134145, gnomAD rs774134145, REVEL 0.04, MetaLR 0.06
- T23S (p.Thr23Ser), Ensembl rs1019409633, Uncertain significance
- T23T (p.Thr23Thr), rs1469059204, gnomAD 14-102870270-T-C, CADD 0.18
- D24N (p.Asp24Asn), TOPMed rs1888260128
- D24Y (p.Asp24Tyr), cosmic curated COSV61023
- D24D (p.Asp24Asp), rs760845229, gnomAD 14-102870273-C-T, CADD 3.93
- R25C (p.Arg25Cys), rs1293923229, ClinGen CA391069641, cosmic curated COSV10590, ClinVar RCV001350295, REVEL 0.25, MetaLR 0.18, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- R25H (p.Arg25His), rs370955205, ClinGen CA267124571, ClinVar RCV001058429, ClinVar RCV003393826, REVEL 0.22, MetaLR 0.15, Uncertain significance, TRAF3-related disorder; Herpes simplex encephalitis, susceptibility to, 3
- R25L (p.Arg25Leu), rs370955205, ClinGen CA7359151, cosmic curated COSV10069, ClinVar RCV001070062, REVEL 0.25, MetaLR 0.13, Likely benign, Herpes simplex encephalitis, susceptibility to, 3
- R25R (p.Arg25Arg), rs1051749, gnomAD 14-102870276-C-T, CADD 1.81
- S26R (p.Ser26Arg), rs375545964, ClinGen CA7359152, ClinVar RCV004336076, ClinVar RCV006616849, REVEL 0.05, MetaLR 0.08, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- S26N (p.Ser26Asn), gnomAD 14-102870278-G-A, REVEL 0.11, CADD 15.60
- S26S (p.Ser26Ser), rs1296931363, gnomAD 14-102870279-T-C, CADD 0.35
- A27P (p.Ala27Pro), rs759772207, ClinGen CA7359153, cosmic curated COSV61026, ClinVar RCV002651251, REVEL 0.01, MetaLR 0.04, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- G28E (p.Gly28Glu), gnomAD rs1288284677, REVEL 0.01, MetaLR 0.06
- G28R (p.Gly28Arg), gnomAD rs1216821129, REVEL 0.04, MetaLR 0.07
- G28G (p.Gly28Gly), gnomAD 14-102870285-G-A, CADD 1.51
- T29M (p.Thr29Met), rs547180445, ClinGen CA7359154, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61025, REVEL 0.06, MetaLR 0.07, Uncertain significance, not provided; Herpes simplex encephalitis, susceptibility to, 3
- T29P (p.Thr29Pro), cosmic curated COSV61026, MetaLR 0.04, MetaSVM -1.04
- T29A (p.Thr29Ala), gnomAD 14-102870286-A-G, REVEL 0.02, CADD 0.34
- T29T (p.Thr29Thr), rs1222723657, gnomAD 14-102870288-G-A, CADD 0.15
- P30L (p.Pro30Leu), gnomAD rs1255313438, MetaLR 0.07, MetaSVM -0.97
- P30P (p.Pro30Pro), gnomAD 14-102870291-A-G, CADD 0.23
- V33V (p.Val33Val), rs1566786027, gnomAD 14-102870300-C-T, CADD 8.53
- P34S (p.Pro34Ser), NCI-TCGA Cosmic COSV1006, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61027, TOPMed rs1888262732, REVEL 0.22, MetaLR 0.17, Variant assessed as somatic; moderate impact.
- P34T (p.Pro34Thr), cosmic curated COSV10069, MetaLR 0.19, MetaSVM -0.86
- P34L (p.Pro34Leu), gnomAD 14-102870302-C-T, REVEL 0.23, CADD 25.40
- P34P (p.Pro34Pro), gnomAD 14-102870303-T-C, CADD 4.79
- E35* (p.Glu35Ter), cosmic curated COSV10465
- E35K (p.Glu35Lys), ExAC rs753068608, gnomAD rs753068608, REVEL 0.18, MetaLR 0.08
- E35E (p.Glu35Glu), rs1566786044, gnomAD 14-102870306-A-G, CADD 9.12
- Q36* (p.Gln36Ter), cosmic curated COSV10741
- Q36R (p.Gln36Arg), gnomAD 14-102870308-A-G, REVEL 0.06, CADD 19.10
- G37* (p.Gly37Ter), cosmic curated COSV10069
- G37A (p.Gly37Ala), cosmic curated COSV61027
- G37E (p.Gly37Glu), ExAC rs758854542, gnomAD rs758854542, REVEL 0.28, MetaLR 0.14
- G37G (p.Gly37Gly), rs1388999330, gnomAD 14-102870312-A-G, CADD 3.27
- Y39C (p.Tyr39Cys), rs147686384, cosmic curated COSV61025, ESP rs147686384, TOPMed rs147686384, AlphaMissense 0.82, MetaLR 0.27, Variant assessed as somatic; moderate impact.
- Y39T (p.Tyr39Thr), NCI-TCGA TCGA novel, MetaLR 0.21, MetaSVM -0.75, Variant assessed as somatic; high impact.
- Y39Y (p.Tyr39Tyr), gnomAD 14-102870318-C-T, CADD 9.07
- K40E (p.Lys40Glu), rs764715452, ClinGen CA7359157, ClinVar RCV001927786, ExAC rs764715452, REVEL 0.24, MetaLR 0.04, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- K40M (p.Lys40Met), cosmic curated COSV61027, MetaLR 0.17, MetaSVM -0.83
- K40R (p.Lys40Arg), gnomAD 14-102870320-A-G, REVEL 0.06, CADD 19.20
- K40N (p.Lys40Asn), gnomAD 14-102870321-G-C, REVEL 0.07, CADD 16.60
- K40K (p.Lys40Lys), rs1888264111, gnomAD 14-102870321-G-A, CADD 8.07
- E41G (p.Glu41Gly), TOPMed rs1888264298
- E41K (p.Glu41Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E41E (p.Glu41Glu), gnomAD 14-102870324-A-G, CADD 7.26
- K42E (p.Lys42Glu), rs2542430783, ClinGen CA391069748, ClinVar RCV003106964, REVEL 0.15, MetaLR 0.14, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- K42N (p.Lys42Asn), rs751980343, ClinGen CA7359158, ClinVar RCV004357274, ExAC rs751980343, REVEL 0.10, MetaLR 0.17, Uncertain significance, not specified
- K42K (p.Lys42Lys), rs751980343, gnomAD 14-102870327-G-A, CADD 9.93
- F43L (p.Phe43Leu), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10069, MetaLR 0.39, MetaSVM -0.36, Variant assessed as somatic; moderate impact.
- K45E (p.Lys45Glu), gnomAD 14-102870334-A-G, REVEL 0.25, CADD 18.90
- K45N (p.Lys45Asn), gnomAD 14-102870336-G-C, REVEL 0.17, CADD 17.70
- T46P (p.Thr46Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T46S (p.Thr46Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T46T (p.Thr46Thr), rs201415483, gnomAD 14-102870339-C-G, CADD 0.58
- V47M (p.Val47Met), rs755721963, ClinGen CA7359162, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61026, REVEL 0.27, MetaLR 0.45, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3; not specified
- V47L (p.Val47Leu), gnomAD 14-102870340-G-T, REVEL 0.26, CADD 19.30
- E48D (p.Glu48Asp), gnomAD 14-102870345-G-T, REVEL 0.41, CADD 17.20
- K50K (p.Lys50Lys), gnomAD 14-102870351-G-A, CADD 10.30
- Y51S (p.Tyr51Ser), NCI-TCGA TCGA novel, MetaLR 0.57, MetaSVM 0.22, Variant assessed as somatic; high impact.
- Y51Y (p.Tyr51Tyr), rs1165346141, gnomAD 14-102870354-C-T, CADD 9.04
- K52C (p.Lys52Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K52N (p.Lys52Asn), rs779844990, ClinGen CA7359163, ClinVar RCV001896053, ExAC rs779844990, REVEL 0.26, MetaLR 0.39, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- K52R (p.Lys52Arg), cosmic curated COSV10441, MetaLR 0.36, MetaSVM -0.38
- C53W (p.Cys53Trp), gnomAD 14-102870360-T-G, REVEL 0.89, CADD 22.50
- E54* (p.Glu54Ter), NCI-TCGA Cosmic COSV6102, Variant assessed as somatic; high impact.
- E54Q (p.Glu54Gln), cosmic curated COSV61026
- E54G (p.Glu54Gly), gnomAD 14-102870362-A-G, REVEL 0.35, CADD 23.20
- K55* (p.Lys55Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K55N (p.Lys55Asn), cosmic curated COSV10888
- K55E (p.Lys55Glu), gnomAD 14-102870364-A-G, REVEL 0.22, CADD 22.50
- K55T (p.Lys55Thr), gnomAD 14-102870365-A-C, REVEL 0.27, CADD 22.30
- K55K (p.Lys55Lys), rs1555373885, gnomAD 14-102870366-G-A, CADD 10.80
- C56G (p.Cys56Gly), cosmic curated COSV61027, MetaLR 0.95, MetaSVM 1.10
- C56F (p.Cys56Phe), gnomAD 14-102870368-G-T, REVEL 0.96, CADD 28.00
- H57Y (p.His57Tyr), ExAC rs749156219, TOPMed rs749156219, gnomAD rs749156219, REVEL 0.17, MetaLR 0.26
- L58L (p.Leu58Leu), rs1320215320, gnomAD 14-102870373-C-T, CADD 10.20
- V59A (p.Val59Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V59E (p.Val59Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V59M (p.Val59Met), TOPMed rs1888266286, MetaLR 0.44, MetaSVM -0.19
- V59V (p.Val59Val), rs1888266464, gnomAD 14-102870378-G-A, CADD 9.33
- L60L (p.Leu60Leu), gnomAD 14-102870379-C-T, CADD 9.99
- L60P (p.Leu60Pro), gnomAD 14-102870380-T-C, REVEL 0.88, CADD 28.90
- C61G (p.Cys61Gly), gnomAD rs1385981615, REVEL 0.58, MetaLR 0.39
- S62N (p.Ser62Asn), rs183443558, ClinGen CA7359165, ClinVar RCV001882318, ClinVar RCV004041472, REVEL 0.15, MetaLR 0.12, Conflicting interpretations, not specified; Herpes simplex encephalitis, susceptibility to, 3
- S62C (p.Ser62Cys), gnomAD 14-102870385-A-T, REVEL 0.29, CADD 23.60
- S62I (p.Ser62Ile), gnomAD 14-102870386-G-T, REVEL 0.20, CADD 19.20
- P63L (p.Pro63Leu), rs1888267235, ClinGen CA391069899, cosmic curated COSV10069, ClinVar RCV001208799, AlphaMissense 0.99, MetaLR 0.81, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- P63R (p.Pro63Arg), cosmic curated COSV10606
- P63P (p.Pro63Pro), rs142350527, gnomAD 14-102870390-G-A, CADD 1.48
- K64K (p.Lys64Lys), rs748019544, gnomAD 14-102870393-G-A, CADD 8.96
- Q65* (p.Gln65Ter), NCI-TCGA Cosmic COSV6102, cosmic curated COSV61027, Variant assessed as somatic; high impact.
- Q65Q (p.Gln65Gln), rs1229446378, gnomAD 14-102870396-G-A, CADD 9.10
- T66S (p.Thr66Ser), gnomAD 14-102870397-A-T, REVEL 0.63, CADD 25.00
- T66T (p.Thr66Thr), rs1275435989, gnomAD 14-102870399-C-G, CADD 0.28
- E67D (p.Glu67Asp), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10069, REVEL 0.36, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- E67K (p.Glu67Lys), rs1566786155, ClinGen CA391069923, NCI-TCGA Cosmic COSV6102, cosmic curated COSV61025, REVEL 0.46, MetaLR 0.32, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- C68R (p.Cys68Arg), gnomAD 14-102870403-T-C, REVEL 0.93, CADD 27.70
- C68F (p.Cys68Phe), gnomAD 14-102870404-G-T, REVEL 0.96, CADD 27.50
- G69G (p.Gly69Gly), gnomAD 14-102870408-G-A, CADD 2.89
- H70H (p.His70His), rs776782540, gnomAD 14-102870411-C-T, CADD 9.13
- R71H (p.Arg71His), rs1888269338, ClinGen CA391069957, cosmic curated COSV61023, ClinVar RCV002031299, REVEL 0.68, MetaLR 0.58, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- R71P (p.Arg71Pro), Ensembl rs1888269338, MetaLR 0.63, MetaSVM 0.34, Uncertain significance
- C73C (p.Cys73Cys), rs759871810, gnomAD 14-102870420-C-T, CADD 0.89
- E74D (p.Glu74Asp), ExAC rs765509930, TOPMed rs765509930, gnomAD rs765509930, REVEL 0.12, MetaLR 0.19
- E74E (p.Glu74Glu), rs765509930, gnomAD 14-102870423-G-A, CADD 7.51
- S75G (p.Ser75Gly), gnomAD 14-102870424-A-G, REVEL 0.27, CADD 22.30
- C76S (p.Cys76Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C76Y (p.Cys76Tyr), cosmic curated COSV61026, MetaLR 0.93, MetaSVM 1.06
- C76G (p.Cys76Gly), gnomAD 14-102870427-T-G, REVEL 0.86, CADD 27.00
- C76C (p.Cys76Cys), gnomAD 14-102870429-C-T, CADD 8.87
- A78E (p.Ala78Glu), cosmic curated COSV61023, ExAC rs775556588, TOPMed rs775556588, gnomAD rs775556588, REVEL 0.16, MetaLR 0.14, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- A78S (p.Ala78Ser), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10069, Variant assessed as somatic; moderate impact.
- A78V (p.Ala78Val), rs775556588, ClinGen CA7359172, ClinVar RCV001919378, ClinVar RCV004877718, REVEL 0.15, MetaLR 0.15, Uncertain significance, not specified; Herpes simplex encephalitis, susceptibility to, 3
- A78A (p.Ala78Ala), rs916514561, gnomAD 14-102870435-G-A, CADD 0.17
- A79S (p.Ala79Ser), Ensembl rs1888270755
- A79V (p.Ala79Val), Ensembl rs1566786206, MetaLR 0.25, MetaSVM -0.88
- A79D (p.Ala79Asp), gnomAD 14-102870437-C-A, REVEL 0.09, CADD 6.51
- L80M (p.Leu80Met), cosmic curated COSV10069
- L80L (p.Leu80Leu), gnomAD 14-102870439-C-T, CADD 1.82
- S82C (p.Ser82Cys), cosmic curated COSV61026, MetaLR 0.39, MetaSVM -0.28
- S82I (p.Ser82Ile), rs1235290905, NCI-TCGA Cosmic COSV1006, cosmic curated COSV10069, gnomAD rs1235290905, REVEL 0.39, MetaLR 0.37, Variant assessed as somatic; moderate impact.
- S82R (p.Ser82Arg), rs146435455, ClinGen CA7359204, ClinVar RCV002952561, ESP rs146435455, REVEL 0.18, MetaLR 0.15, Uncertain significance, Herpes simplex encephalitis, susceptibility to, 3
- S83K (p.Ser83Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
Public TRAF3 analysis runs
- TRAF3 analysis run — TRAF3 (841 variants) — completed 2026-08-20